Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis

Background: The new heart failure (HF) therapies of sodium-glucose cotransporter 2 inhibitors (SGLT2i), vericiguat, and omecamtiv mecarbil do not act primarily through the neuro-hormonal blockade, but have shown clinical benefits in patients with HF with reduced ejection fraction (HFrEF). However, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagnesi, Matteo, Baldetti, Luca, Aimo, Alberto, Inciardi, Riccardo Maria, Tomasoni, Daniela, Vizzardi, Enrico, Vergaro, Giuseppe, Emdin, Michele, Lombardi, Carlo Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777808/
https://www.ncbi.nlm.nih.gov/pubmed/35054042
http://dx.doi.org/10.3390/jcm11020348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777808/
https://www.ncbi.nlm.nih.gov/pubmed/35054042
http://dx.doi.org/10.3390/jcm11020348

Ejemplares similares